Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program
Current TAP Partner
CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.
"LLS has a long-standing history of helping to accelerate development of breakthrough blood cancer treatments, and we're particularly excited when work like Rgenta's focuses on key mechanisms in blood cancer that have historically been extremely difficult to target with drugs" said Lore Gruenbaum, Ph.D., Vice President of LLS TAP. "This new partnership is an exciting addition to LLS TAP's portfolio of companies that are working to provide new hope to all blood cancer patients."